8-K: Paysign Inc. Reports Strong Second Quarter 2024 Results, Driven by Growth in Plasma and Patient Affordability Programs

Paysign, Inc. announced a significant increase in revenue and profitability for the second quarter of 2024, driven by strong growth in both its plasma and patient affordability businesses.

Summary

• Paysign reported total revenues of $14.33 million for the second quarter of 2024, a 29.8% increase compared to the same period in 2023.
• The company achieved a net income of $697 thousand, or $0.01 per diluted share, a significant improvement from a net loss of $104 thousand in the second quarter of 2023.
• Adjusted EBITDA for the quarter was $2.24 million, a 95.8% increase year-over-year, with diluted Adjusted EBITDA per share at $0.04.
• Plasma revenue increased by 12.6% due to an increase in plasma locations and donations, with the total plasma center count reaching 477.
• Pharma patient affordability revenue saw a substantial increase of 266.8%, driven by the addition of eight net new programs, bringing the total to 61 active programs.
• The company's gross profit margin improved to 52.9%, up from 50.9% in the prior year.
• Paysign exited the quarter with $31.29 million in unrestricted cash and no debt.
• The company has raised its full-year revenue guidance to a range of $56.5 million to $58.5 million, reflecting a 20% to 24% year-over-year growth.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to the strong financial results, significant growth in key business segments, and raised full-year guidance. The company's performance is well above expectations, and management's comments are optimistic.

Positives

• Paysign experienced substantial revenue growth of 29.8% year-over-year.
• The company achieved a significant turnaround in profitability, moving from a net loss to a net income of $697 thousand.
• Adjusted EBITDA nearly doubled, increasing by 95.8%.
• The patient affordability business saw exceptional growth, with a 266.8% increase in revenue.
• The company's gross margin improved by 207 basis points.
• Paysign has a strong cash position with $31.29 million in unrestricted cash and no debt.
• The company raised its full-year revenue guidance, indicating confidence in future performance.
• The average revenue per plasma center per month increased by 4.4% to $7,916.

Negatives

• Cost of revenues increased by 24.3%, primarily due to increased cardholder usage and network expenses.
• Selling, general, and administrative expenses increased by 13.5%, driven by increased compensation and benefits.
• Depreciation and amortization expenses increased by 50.3% due to continued capitalization of software development costs.
• The income tax provision increased due to changes in the company's valuation allowance and tax benefits related to stock-based compensation.

Risks

• The company's future growth rate may not be sustainable.
• A downturn in the economy could reduce the customer base and demand for Paysign's products and services.
• Operating in a highly regulated environment poses compliance risks.
• Data security breaches could expose the company to liability and litigation.
• Changes in laws, regulations, or industry standards could negatively impact the business.

Future Outlook

Paysign has raised its full-year revenue guidance to $56.5 million to $58.5 million, with plasma revenue expected to account for approximately 78% of total revenue and pharma revenue approximately 20%. The company expects gross profit margins between 54.0% and 55.0%, operating expenses between $30.0 million and $32.0 million, and net income between $2.0 million and $3.0 million. Adjusted EBITDA is expected to be between $9.0 million and $10.0 million.

Management Comments

• We are extremely pleased with Paysigns second-quarter financial results, as we continue to grow our business at a rapid pace, stated Mark Newcomer, President & CEO of Paysign.
• Looking forward, we anticipate maintaining our current trajectory across our two major businesses of plasma donor compensation and pharma patient affordability while seeking additional high growth opportunities within the payments space.
• We remain committed to delivering sustainable growth and maximizing shareholder value.
• Due to the outperformance of our business during the first two quarters of the year relative to our initial expectations, we are raising our full year guidance, said Jeff Baker, Paysign CFO.

Industry Context

Paysign's strong performance reflects the growing demand for digital payment solutions in the healthcare industry, particularly in the areas of plasma donation and patient affordability programs. The company's focus on these niche markets positions it well to capitalize on industry trends.

Comparison to Industry Standards

• Paysign's 29.8% revenue growth significantly outpaces the average growth rate for payment processing companies, which typically see growth in the low to mid-teens.
• The 95.8% increase in adjusted EBITDA is exceptional compared to industry peers, indicating strong operational efficiency and profitability.
• Companies like Wex Inc. and FleetCor Technologies, Inc., which also operate in the payment solutions space, have reported more modest growth rates in recent quarters.
• Paysign's focus on the healthcare sector, particularly plasma and patient affordability, differentiates it from broader payment processors, allowing for higher growth in these specific areas.
• The company's gross margin of 52.9% is competitive with other payment processors, but the significant increase in margin suggests a positive shift in the business mix towards higher-margin patient affordability programs.

Stakeholder Impact

• Shareholders will benefit from the increased profitability and raised guidance.
• Employees may see continued hiring and compensation increases.
• Customers will benefit from the expansion of Paysign's services and programs.
• Suppliers and creditors will benefit from the company's improved financial health.

Next Steps

• The company will hold a conference call on July 31, 2024, to discuss the second quarter 2024 financial results.
• Paysign will continue to focus on growing its plasma donor compensation and pharma patient affordability businesses.
• The company will seek additional high-growth opportunities within the payments space.

Key Dates

Keywords

Paysign, prepaid cards, patient affordability, plasma, financial results, EBITDA, revenue, healthcare, fintech, payment processing